Endoscopy 2022; 54(S 01): S28
DOI: 10.1055/s-0042-1744614
Abstracts | ESGE Days 2022
ESGE Days 2022 Oral presentations
13:30-14:30 Thursday, 28 April 2022 Club H. Accessing the gallbladder and bile duct

LONG-TERM PATENCY AND NEED-FOR-REINTERVENTIONS OF EUS-GUIDED CHOLEDOCODUODENOSTOMY WITH ELECTROCAUTERY-ENHANCED LUMEN APPOSING METAL STENTS: A SINGLE-CENTRE PROSPECTIVE EVALUATION.

G. Vanella
1   IRCCS San Raffaele Scientific Institute, Pancreatobiliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, Milan, Italy
,
G. Dell'Anna
1   IRCCS San Raffaele Scientific Institute, Pancreatobiliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, Milan, Italy
,
L. Archibugi
1   IRCCS San Raffaele Scientific Institute, Pancreatobiliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, Milan, Italy
,
M.C. Petrone
1   IRCCS San Raffaele Scientific Institute, Pancreatobiliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, Milan, Italy
,
P.G. Arcidiacono
1   IRCCS San Raffaele Scientific Institute, Pancreatobiliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, Milan, Italy
› Author Affiliations
 

Aims EUS-guided Choledocho-Duodenostomy (EUS-CD) with electrocautery-enhanced Lumen Apposing Metal Stents (ec-LAMS) is an established alternative for biliary drainage in patients with distal malignant biliary obstruction (dMBO) in whom conventional retrograde drainage fails. However, long-term prospective evaluations are lacking

Methods All consecutive EUS-CD with ec-LAMS performed in a tertiary academic centre between 2017-2021 were included. Patients with follow-up (FU) > 30 days were included for prospective analysis of recurrence rate and reinterventions. Dysfunction-Free Survival (DFS) probability was estimated by Kaplan-Meier statistics.

Results Forty-seven patients (male 57.4%; median age 71 [64-77], 89.4% pancreatic cancer) underwent EUS-CD with ec-LAMS (Hot-Axios, Boston Scientific, Marlborough, US). Mean procedural time was 5 (3-6.2) min. Technical and clinical success were 97.9% and 91.3% respectively. Adverse events were registered in 5 patients (10.6%), including technical/clinical failures. Among 30 prospectively followed patients with > 30 days (median 108 [62-255] days) of FU, 9 (30%) dysfunction cases (8 stones/food impactions and 1 stent migration) were registered. Median time-to-dysfunction was 255 [156-305] days. In almost all cases (8/9, 88.9%) endoscopic reinterventions (stone extraction, LAMS exchange, conversion to ERCP or EUS-hepaticogastrostomy) were successful. 6- and 12-months probability of stent dysfunction was 7.7% and 59% respectively at Kaplan-Meier curve, with an estimated median DFS of 364 (95%CI 255-412) days.

Conclusions As EUS-CD spreads, recurrence might be a frequent long-term issue, comparable to the rate reported for retrograde biliary SEMS. Clinicians should be aware that endoscopic revision is effective and safe in almost all cases. (PROTECT Registry, ClinicalTrials.gov NCT04813055).



Publication History

Article published online:
14 April 2022

© 2022. European Society of Gastrointestinal Endoscopy. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany